Apple Bites Back in China: How iPhone Turned a Market Slump into a Power Move -( $AAPL $DIA $SPY $QQQ )

Apple’s (AAPL) latest China sales story reads less like a tech obituary and more like a plot twist: in a sharply contracting smartphone market, the iPhone has quietly slipped back into a lead role, powered by price discipline, bigger storage, and a marquee flagship that Chinese consumers still line up to photograph before they buy. While domestic rivals are nursing double‑digit declines, Apple is doing something unfashionable in the world’s toughest handset arena: growing.

A Rebound In A Slump

China’s smartphone market has been stuck in reverse, with unit sales in January down roughly 23% year over year as consumers pull back and promotional calendars shift. In that context, any growth at all qualifies as a feat, which makes Apple’s mid‑single‑digit to double‑digit sales gains stand out like a green bar in a sea of red.

Research firm Counterpoint notes that Apple was the only major brand to post a year‑on‑year sales increase in China to start 2026, even as names like Huawei and Xiaomi absorbed steep declines. Market data show overall demand sagging while the iPhone 17 series continues to move, lifting Apple’s share to some of its highest January levels in years.

The iPhone 17 Effect

The turnaround has a protagonist: the iPhone 17 line, which has delivered a far cleaner launch than its predecessor and now accounts for the bulk of Apple’s China smartphone sell‑through. In the first month after launch, iPhone sales in China jumped more than 20% year over year, with the new series representing close to 80% of Apple’s units in that window.

Analysts point out that the 17 Pro’s camera redesign and the decision to double base storage at the same sticker price have helped reframe value for Chinese buyers who have no shortage of local alternatives. The result has been the kind of old‑fashioned launch‑day spectacle—crowds outside Beijing flagships, selfie lines longer than the checkout queue—that marketers in slower categories can only envy.

From Discounts To Discipline

The current strength arrives not long after Apple fought off a bout of indigestion in China, when iPhone 15 models needed unusually aggressive discounting to keep pace with Huawei and Xiaomi. At the time, resellers were cutting prices by well over one hundred dollars per device, and Apple itself dipped into official promotions around major shopping festivals—moves that raised uncomfortable questions about brand elasticity at the premium end.

Those cuts did their job, helping stabilize share while the company regrouped on hardware and supply, even if they squeezed margins and emboldened domestic rivals to play the same game. Now, with the iPhone 17 cycle in full swing and unit trends positive against a declining market, Apple appears to be relying more on product pull and less on sticker shock therapy.

Market Share Moves And Rivals

In the closing stretch of last year and into early 2026, Apple has climbed back toward the top of the Chinese smartphone leaderboard, with quarterly share estimates in the low‑20s as the 17 family ramps. That push has come partly at the expense of domestic incumbents, as Huawei, Vivo, and Xiaomi ceded ground while navigating their own slowdowns and inventory clean‑ups.

Even so, this is no victory lap: Huawei still leads in some recent monthly snapshots, and local brands remain formidable in both innovation and price engineering. The more relevant storyline for investors is not that Apple has “won” China, but that it has re‑entered the conversation as a share‑gainer in a market where growth itself has become a scarce asset.

What It Means For Investors

For shareholders, China’s latest numbers suggest that fears of a one‑way slide may have been premature, particularly given how quickly momentum has flipped from discounted iPhone 15s to a premium‑priced 17 cycle that is adding volume in a contracting market. With Apple reclaiming high‑teens to mid‑20s market share in the country at various points and demonstrating that a well‑timed flagship can still move the needle, the region looks less like a structural drag and more like a high‑beta amplifier for the broader iPhone franchise.

The risk, of course, is that China’s macro malaise and relentless local competition reduce this latest rebound to just another chapter in an increasingly cyclical saga. For now, though, Apple has pulled off something every portfolio manager secretly admires: growing in a shrinking pie, and charging enough for the privilege that the story still reads like a business section, not the clearance aisle.

The Sources

[1] iPhone sales in China grew in January despite massive market slump https://finance.yahoo.com/news/iphone-sales-china-grew-january-144830055.html
[2] Apple’s Huge Surge in China – Yahoo Finance https://finance.yahoo.com/news/apple-huge-surge-china-141541634.html
[3] China’s January smartphone sales down 23% Y/Y, says Counterpoint https://www.reuters.com/business/media-telecom/chinas-january-smartphone-sales-down-23-yy-says-counterpoint-2026-02-12/
[4] China Smartphone Sales Fall 23% in January 2026 – IndexBox https://www.indexbox.io/blog/china-smartphone-sales-fall-23-in-january-2026/
[5] China’s smartphone sales fell 23% year over year in January 2026 … https://www.facebook.com/groups/iosbeta/posts/1746386409668233/
[6] Apple’s China iPhone sales jumped 22% in month after iPhone 17 … https://finance.yahoo.com/news/apples-china-iphone-sales-jumped-071838504.html
[7] Apple Sees 22% Jump in China iPhone Sales After iPhone 17 Launch https://finance.yahoo.com/news/apple-sees-22-jump-china-160922338.html
[8] Apple slashed iPhone prices in China. Sales are bouncing back – CNN https://www.cnn.com/2024/05/29/tech/china-apple-sales-rebound-price-cuts-intl-hnk
[9] Apple’s iPhone Steeply Discounted in China on Weak Demand https://www.bloomberg.com/news/articles/2024-02-29/apple-s-iphone-steeply-discounted-in-china-on-weak-demand
[10] Chinese retailers are already slashing the prices of the iPhone 15 by … https://finance.yahoo.com/news/chinese-retailers-already-slashing-prices-112708745.html
[11] Apple offers a rare $70 discount on the iPhone 15 in China … – Fortune https://fortune.com/asia/2024/01/15/apple-offers-discount-china-iphone-huawei-honor-smartphone/
[12] Apple Just Claimed the Top Spot in the Chinese Smartphone Market … https://finance.yahoo.com/news/apple-just-claimed-top-spot-215030826.html
[13] Apple Jumps to 25% Market Share in China – Yahoo Finance https://finance.yahoo.com/news/apple-jumps-25-market-share-112838813.html
[14] Apple’s iPhone sales struggle in China, focusing on AI https://finance.yahoo.com/video/apples-iphone-sales-struggle-china-163940444.html
[15] Apple stock rises after report shows China iPhone sales increasing … https://www.youtube.com/watch?v=AMMyD4Bsw7k

by John F. Heerdink, Jr. March 19, 2026

When Bangles Meet Bankers: Inside India’s Glittering Gold-Loan Boom -( $GLD )

India’s gold-backed lending boom is turning family heirlooms into the country’s most hardworking asset class, as households and small businesses increasingly march into bank branches with bangles instead of balance sheets. Rising gold prices, looser lending rules, and a vast, underutilized stockpile of household bullion are quietly transforming India’s credit market while giving bankers a glittering new growth engine.

India’s New Love Language: Collateral

For decades, gold in India largely sat in lockers, surfacing for weddings, festivals, and the occasional family argument over inheritance. Now it has acquired a second career as collateral, fueling a surge in loans that is growing far faster than most other forms of retail credit.

Bank loans against gold have jumped well into triple-digit year-on-year growth, outpacing overall credit expansion by a wide margin.
Non-bank finance companies (NBFCs), long the specialists in gold loans, are being joined by aggressive banks narrowing the gap in what is now nearly a 50-50 market.

The result is that gold, once treated as a sentimental dead asset, is becoming a mainstream funding tool for shopkeepers, farmers, and micro-entrepreneurs who prefer to pledge jewellery rather than navigate traditional underwriting.

A Trillion-Dollar Piggy Bank Unlocks

India’s households are estimated to hold roughly 34,000-plus tonnes of gold, worth several trillion dollars at current prices—more than the country’s entire annual economic output by some estimates. That hoard, historically immune to modern finance, is finally being coaxed into the formal system.

Rising domestic prices, with benchmark contracts hovering near record highs in rupee terms, have boosted the borrowing capacity per gram and made gold-backed credit particularly attractive.
As awareness grows that owners can unlock liquidity without selling or melting heirlooms, demand for short-tenor, small-ticket loans has accelerated across both urban and rural markets.

In effect, India is discovering that the national piggy bank was never in the banking system at all—it was in velvet-lined boxes tucked under beds and behind cupboard drawers.

Policy Tailwinds and Competitive Fire

Regulation, often cast as a brake on financial exuberance, is in this case acting more like a judicious accelerator. The Reserve Bank of India has allowed higher loan-to-value ratios for small-ticket gold loans and clarified classification norms, making it easier for lenders to scale this secured segment while staying within prudential guardrails.

For loans up to a modest size, lenders can advance a larger share of the pledged value, with streamlined credit appraisal for smaller customers, especially in rural and low-income segments.
NBFCs have been rapidly adding branches, while banks sharpen pricing and distribution to win share in a market now viewed as structurally important, not just a cyclical side business.

The competitive intensity is turning gold loans from a niche product into a flagship line item, with management teams discussing branch additions and portfolio growth targets in the same breath as mortgages and personal credit.

From Stigma to Strategy

There was a time when walking into a gold-loan branch carried a faint social stigma, as if pledging jewellery signaled distress rather than discipline. That perception is steadily eroding as micro, small, and medium enterprises (MSMEs) discover that quickly monetizing gold can be a cheaper, cleaner way to manage working capital than unsecured borrowing or informal moneylenders.

Business owners now use gold loans tactically to bridge seasonal cash-flow gaps, fund inventory, or finance short-cycle opportunities, repaying in months rather than years.
The shift from informal pawnbrokers to regulated banks and NBFCs brings clearer contracts, better disclosures, and tighter consumer protections, helping normalize the product in the eyes of the middle class.

In a country where credit scores can be fragile but wedding jewellery is abundant, gold is becoming the great equalizer in access to formal finance.

What It Signals for Investors

For investors scanning India’s financial landscape, the gold loan boom offers both a cyclical play on bullion prices and a structural story about financial inclusion and balance-sheet prudence.

Lenders like specialized gold-loan NBFCs and banks with strong secured retail franchises may see higher-yielding growth with relatively contained credit risk, given the daily mark-to-market nature of the collateral.
At the macro level, every gram of jewellery that migrates from the locker to the loan book deepens financial intermediation, supporting consumption and small-business investment without leaning excessively on unsecured credit.

If India’s households once treated gold as an insurance policy against uncertainty, they are increasingly discovering a second function: a flexible, interest-bearing bridge between aspiration and balance-sheet reality—no alchemy required, just a trip to the branch with a neatly labelled jewellery box.

The Sources

[1] How rising prices are driving a boom in India’s gold loan sector https://www.cnbctv18.com/personal-finance/how-rising-prices-are-driving-a-boom-in-india-gold-loan-sector-ws-el-19858558.htm
[2] India holds 34,600 tonnes of gold, 3.1x the value of current equity … https://www.ibef.org/news/india-holds-34-600-tonnes-of-gold-3-1x-the-value-of-current-equity-holding
[3] Bank Loans Against Gold Rise 125% in a Year: RBI Data – Angel One https://www.angelone.in/news/market-updates/bank-loans-against-gold-rise-125-in-a-year-rbi-data
[4] India’s household gold reserves exceed GDP at 140% with 67% in … https://www.linkedin.com/posts/vaibhavjain87_morgan-stanley-reports-that-indian-households-activity-7421075131571068928-GpQN
[5] India’s Gold Loan Boom: RBI Data Reveals STUNNING Triple-Digit … https://www.whalesbook.com/news/English/bankingfinance/Indias-Gold-Loan-Boom-RBI-Data-Reveals-STUNNING-Triple-Digit-Growth-Outpacing-Banks/694a59e0f0e07fab8a7db105
[6] Banks narrow NBFCs’ lead as India’s gold loan market turns nearly … https://economictimes.com/industry/banking/finance/banks-narrow-nbfcs-lead-as-indias-gold-loan-market-turns-nearly-50-50/articleshow/126421874.cms
[7] $5 trillion in gold? At record high prices, India’s household gold … https://economictimes.com/markets/stocks/news/5-trillion-in-gold-at-record-high-prices-indias-household-gold-could-now-be-bigger-than-gdp/articleshow/126223934.cms
[8] Gold nears one-month high, set for seventh straight monthly rise https://www.cnbc.com/2026/02/27/gold-heads-for-seventh-straight-monthly-gain-on-safe-haven-demand.html
[9] Gold near ₹1.57 lakh per 10 grams on MCX, silver gains 2% https://www.cnbctv18.com/market/commodities/gold-silver-prices-india-mcx-gain-rise-global-factors-investment-ws-el-19869814.htm
[10] Gold slips over 1% on strong dollar, easing rate-cut bets – CNBC https://www.cnbc.com/2026/03/12/gold-treads-water-as-margin-calls-strong-dollar-offset-safety-demand.html
[11] RBI’s New Gold Loan Rules to Boost NBFC Growth: Crisil – Enterslice https://enterslice.com/learning/crisil-ratings-rbi-revised-gold-loan-norms-encourage-nbfc-expansion/
[12] Most Indians Are Holding Gold & Taking Gold Loans Rather Than … https://www.youtube.com/watch?v=M8qi2bTrgAY
[13] Gold Prices Have Been On The Rise, Leading To An Increase In … https://www.youtube.com/watch?v=DN_eguCVZb0
[14] India’s Gold Loan Sector Surges 42% to ₹15.6 Lakh Crore – LinkedIn https://www.linkedin.com/posts/cnbc-tv18_goldprices-gold-goldprice-activity-7432735751332823040-X0KW
[15] Stanchart: Gold ripe for correction near-term but to lift off in 2026 https://www.cnbc.com/video/2025/10/21/gold-prices-ripe-for-correction-near-term-but-to-lift-off-in-26.html

by John F. Heerdink, Jr. March 18, 2026

Serina Therapeutics Secures 30 Million Reasons Wall Street Is Warming to Parkinson’s Innovation -( $SER $IBB $XBI )

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns.

Parkinson’s Bet Draws Fresh Capital

In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.

What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page.

Fueling a Registrational Parkinson’s Trial

This new funding is earmarked to advance SER-252, Serina’s lead candidate for advanced Parkinson’s disease, through a Phase 1b registrational trial being conducted under the U.S. Food and Drug Administration’s 505(b)(2) pathway. The company has already dosed the first patient in that study, an early milestone that gives the financing an unusually direct line of sight to value-creating clinical readouts.

SER-252 marries apomorphine—a well-known therapy for Parkinson’s “off” episodes—with Serina’s POZ polymer technology, aiming to replace pumps and tubing with discreet, twice-weekly subcutaneous injections that are designed to maintain a more continuous “on” state. It is a straightforward proposition with ambitious implications: take a proven drug, re-engineer its delivery profile, and in the process potentially redraw the standard of care for some of the 250,000 advanced Parkinson’s patients across the U.S. and Europe who remain inadequately controlled.

The Polymer Platform Behind the Pitch

Underpinning Serina’s clinical story is its POZ platform, a synthetic poly(2-oxazoline) polymer engineered to fine-tune drug loading and control the rate of release for attached small-molecule therapies delivered via subcutaneous injection. The company’s approach is to focus on well-understood, marketed drugs that are held back by tricky pharmacokinetics—short half-lives, toxicity, or unhelpful side-effect profiles—and use POZ to smooth out those limitations by maintaining more stable blood levels over time.home+2

Serina also has an eye on partnership leverage: its POZ technology is positioned for use across a broad range of payloads and indications, and the company has already entered a non-exclusive license agreement with Pfizer to explore its polymers in lipid nanoparticle drug delivery formulations. That kind of platform optionality gives the story more than one way to win, a trait not lost on investors who prefer pipelines that look more like multi-lane highways than cul-de-sacs.

Warrant Sweetener Extends the Runway

The financing arrives with an extra layer of optionality in the form of 50 percent warrant coverage, giving investors the right to purchase additional shares at 5 dollars, a level that represents a substantial premium to recent trading. If fully exercised, warrants associated with the first tranche alone could bring in roughly 16.7 million dollars, with the overall structure providing up to 33.3 million dollars in incremental proceeds and extending Serina’s cash runway into the second half of 2027.

For a clinical-stage biotech, a visible runway into late 2027 buys crucial time to generate and interpret data, navigate regulatory interactions, and explore strategic partnerships without relying on hurried follow-on offerings. It also provides a clearer framework for investors trying to model dilution and valuation in a sector where the capital structure can change faster than a Phase 1 protocol.

SER Shares Perk Up After Hours

On the tape, Serina’s (SER) stock has been anything but static, trading with the kind of volatility investors have come to expect from early-stage neurology names. The premium-priced financing and extended runway, however, appear to have reset sentiment, with shares trading higher in the aftermarket as investors digested the terms and the explicit link between fresh capital and a registrational Parkinson’s program.

Recent data show an already active market in the name, with daily volume reaching into the millions of shares and a 52-week range that spans from the low single digits to levels several times higher, underscoring how quickly expectations around SER-252 and the POZ platform can translate into price action. With at least one Wall Street analyst assigning a double-digit price target well above current levels, the aftermarket bid suggests that some traders are now willing to pay for the possibility that this financing is more launchpad than lifeline.

A Small-Cap Biotech with Big-Cap Ambitions

Serina enters this new chapter as a classic clinical-stage biotechnology company: no dividend, a research-driven cost structure, and a valuation that rests on the perceived probability that its science can translate into commercial products and partnership economics. By aligning a premium private placement, a clear FDA-blessed 505(b)(2) path, and a platform technology already intriguing a major pharma partner, the company is working to shift its narrative from survival to strategic execution.

For investors, the story will now hinge on how smoothly the SER-252 registrational trial progresses, how convincingly POZ-based delivery can differentiate itself in Parkinson’s care, and whether additional indications or collaborations emerge from the polymer platform. In the meantime, the aftermarket strength in SER suggests that, at least for one night, Wall Street is willing to give this polymer-powered neurology story the benefit of the doubt—and a higher quote.

The Sources

Serina Therapeutics Secures Up to 30 Million in Private Placement (GlobeNewswire)
https://www.globenewswire.com/news-release/2026/03/18/3258597/0/en/Serina-Therapeutics-Secures-up-to-30-Million-in-Private-Placement-to-Advance-Registrational-Trial-and-Platform.html[globenewswire]
Serina Therapeutics Secures Up to 30 Million in Private Placement (StockTitan summary)
https://www.stocktitan.net/news/SER/serina-therapeutics-secures-up-to-30-million-in-private-placement-to-32r6os09g19n.html[stocktitan]
Serina Therapeutics (SER) Secures 30 Million Funding for Parkinson’s Treatment (GuruFocus)
https://www.gurufocus.com/news/8723819/serina-therapeutics-ser-secures-30-million-funding-for-parkinsons-treatment[gurufocus]
Serina Therapeutics Dosing of First Patient in Phase 1b Trial for SER-252 (GlobeNewswire via Yahoo)
https://finance.yahoo.com/news/serina-therapeutics-announces-dosing-first-210500413.html[finance.yahoo]
Serina starts Phase 1b SER-252 Parkinson’s trial (StockTitan)
https://www.stocktitan.net/news/SER/serina-therapeutics-announces-dosing-of-first-patient-in-phase-1b-z698owlwvfzp.html[stocktitan]
Serina Therapeutics, Inc. – Investor Relations News Page
https://investors.serinatx.com/news/default.aspx[investors.serinatx]
Serina Therapeutics Company Website – Technology & Pipeline
https://www.serinatx.com[serinatx]
Serina Therapeutics (SER) Stock Price & Overview
https://stockanalysis.com/stocks/ser/[stockanalysis]
Serina Therapeutics Inc. Stock Price (live quote page example)
https://finance.yahoo.com/quote/SER/[finance.yahoo]
Serina Therapeutics Inc. stock profile (Saxo)
https://www.home.saxo/markets/stocks/ser-xase[home]

by John F. Heerdink, Jr. March 18, 2026

Fiber, Funding, and GPUs: Why This Nokia–Nvidia–KGPCo Triangle Should Be on Investors’ Screens -( $NOK $NVDA )

Nvidia’s (NVDA) billion-dollar bet on Nokia (NOK) adds an AI-powered tailwind to what was already a quietly strategic broadband story for KGPCo and BEAD-focused operators. With GPUs now effectively hitching a ride on fiber builds, the network economy just picked up a new co-pilot.

BEAD Money Meets BABA Reality

The U.S. Broadband Equity, Access, and Deployment (BEAD) program is the largest federal broadband investment in history, but the fine print comes with a three-word constraint: Build America, Buy America. That means operators must not only design networks that work; they must design networks that comply.

Nokia was among the first technology vendors to announce Buy America-compliant products for critical broadband infrastructure and later to self-certify that its U.S.-manufactured fiber broadband lineup meets final NTIA BABA guidelines. KGPCo’s announcement effectively turns that compliance edge into shippable inventory for BEAD award winners who don’t have the luxury of learning procurement the hard way.

KGPCo Steps Into the Fast Lane

Based in Faribault, Minnesota, KGPCo brands itself as North America’s largest supply chain logistics supplier and systems integrator to MSOs, ISPs, municipalities, co-ops, and tribal nations. Its model is simple but strategically potent: sit at the junction of product, logistics, and funding rules—and remove friction for everyone racing to close the digital divide.

By being among the first to stock and make Nokia’s BABA-certified products available, KGPCo gives BEAD awardees immediate access to compliant gear across passive OSP materials and active electronics for both middle-mile and last-mile builds. In a market where “lead time” has often sounded like a euphemism for “good luck,” the company is positioning itself as the broadband equivalent of same-day delivery—without the anonymous brown box.

Nokia’s Compliance Edge Becomes a Commercial Weapon

Nokia has been steadily turning regulation into competitive advantage, pairing its long-standing network pedigree with an aggressive push to certify U.S.-manufactured fiber products under BABA and Buy America rules. The vendor offers certification letters to help BEAD applicants prove compliance, effectively handing operators a ready-made paper trail to go with their hardware.

This partnership lets KGPCo plug Nokia’s certified portfolio straight into its distribution engine, aligning product, documentation, and deployment timelines in one package. In a world where noncompliance can derail grant timelines, the ability to buy once and sleep at night is fast becoming a selling point—and an oddly compelling marketing tagline.

NVDA’s $1 Billion Signal: AI Meets Fiber

In late 2025, Nvidia agreed to invest 1.0 billion dollars in newly issued Nokia shares at a subscription price of 6.01 dollars per share, taking a roughly 2.9 percent ownership stake. The deal is tied to a strategic partnership to develop AI-native 5G-Advanced and 6G radio access networks (AI-RAN) and AI-centric data center networking solutions on Nvidia’s accelerated computing stack.

For Nokia, the capital is earmarked to speed up 5G and 6G RAN software on Nvidia’s CUDA-based platforms and to expand data-center-aligned networking within its Network Infrastructure business—exactly the domains that underpin high-capacity broadband and future AI workloads at the edge. For Nvidia shareholders, the move effectively turns Nokia into a leveraged call option on AI-driven connectivity, creating a tighter link between GPU demand, traffic growth, and the underlying fiber and transport infrastructure Nokia already supplies.

When you overlay that with Nokia’s BABA-certified broadband hardware now flowing through KGPCo’s distribution channels, the story becomes less about a one-off compliance win and more about building the physical rails for an AI-native network era funded by BEAD dollars and quietly co-signed by the market’s favorite ticker. The same rural and regional networks tapping KGPCo for compliant Nokia gear today could be the ones carrying Nvidia-accelerated AI services tomorrow, turning “closing the digital divide” into “opening a new AI revenue column” on future income statements.

Speed, Compliance, and the First-Mover Advantage

As BEAD funding shifts from planning decks to field crews, timing matters as much as throughput. KGPCo’s leadership is explicit: speed plus compliance is the differentiator, and operators that can procure certified gear early gain a first-mover advantage in building out underserved markets.

For BEAD award winners, that means fewer procurement bottlenecks, fewer change orders, and a lower probability of discovering in month 18 that a key component was never compliant to begin with. With Nokia’s BABA-certified products on the shelf instead of only on the roadmap, network planners can design, bid, and build against inventory that actually exists—still a nontrivial luxury in telecom.

The Quiet Power of the Integrator

While vendors often dominate headlines, integrators and distributors increasingly dictate execution speed—and, by extension, competitive outcomes. KGPCo’s broad role across core, transport, and access, plus its alignment with federal funding requirements, lets it act as both supply chain backbone and strategic enabler for providers navigating BEAD, NTIA rules, and local constraints.

No one in this ecosystem gets paid for promises on slide 27; value accrues to those who can turn policy into lit fiber on a timeline Washington can live with. By marrying Nokia’s compliance-first product strategy with Nvidia-backed AI ambitions and its own logistics scale, KGPCo isn’t just stocking shelves—it’s quietly becoming an essential counterparty to anyone who plans to turn federal broadband dollars and the AI supercycle into working, revenue-generating networks.

The Sources

KGPCo among first to make Nokia BABA-compliant products available – Yahoo Finance
https://finance.yahoo.com/news/kgpco-among-first-nokia-baba-120000420.html[finance.yahoo]
Nokia first to self-certify fiber products for use in BEAD – Yahoo Finance
https://finance.yahoo.com/news/nokia-first-self-certify-fiber-130000777.html[finance.yahoo]
KGPCo among first to make Nokia BABA-compliant products available – Moomoo News
https://www.moomoo.com/news/post/66987749/kgpco-among-first-to-make-nokia-baba-compliant-products-available[moomoo]
Nokia press release via KGPCo (Nokia BABA-compliant products, BEAD context) – KGPCo
https://www.kgpco.com/about-us/news-and-resources/nokiapressrelease[kgpco]
Home | KGPCo – company overview and positioning
https://www.kgpco.com[kgpco]
First Nokia Buy America-compliant products roll off Sanmina line – Nokia
https://finance.yahoo.com/news/first-nokia-buy-america-compliant-120000397.html[finance.yahoo]
Nokia Build America Buy America (BABA) certification – Nokia
https://www.nokia.com/broadband-access/rural-broadband/us-government-funding-opportunities/build-america-buy-america-certification/[nokia]
Bell Labs Consulting and broader Nokia networks context – Nokia
https://www.nokia.com/bell-labs/bell-labs-consulting/[nokia]
NVIDIA and Nokia to pioneer the AI platform for 6G – Nokia
https://www.nokia.com/newsroom/nvidia-and-nokia-to-pioneer-the-ai-platform-for-6g–powering-americas-return-to-telecommunications-leadership/[nokia]
Nokia partners with Nvidia – Nokia newsroom
https://www.nokia.com/newsroom/nokia-partners-with-nvidia/[nokia]
Inside information: NVIDIA to make 1.0 billion dollar equity investment in Nokia – Nokia
https://www.nokia.com/newsroom/inside-information-nvidia-to-make-usd-1-billion-equity-investment-in-nokia-in-addition-to-new-strategic-partnership/[nokia]
Nvidia takes 1 billion dollar stake in Nokia – CNBC
https://www.cnbc.com/2025/10/28/nvidia-nokia-ai.html[cnbc]
Nokia stock soars after NVIDIA invests 1 billion dollars – Yahoo Finance
https://finance.yahoo.com/news/nokia-stock-soars-nvidia-invests-161344012.html[finance.yahoo]
Nvidia’s 1 billion dollar stake sends Nokia to decade high on AI hopes – Yahoo Finance
https://finance.yahoo.com/news/nvidias-1-billion-stake-sends-nokia-to-decade-high-on-ai-hopes-[finance.yahoo]
Nokia completes directed share issue to Nvidia – MarketScreener
https://www.marketscreener.com/news/nokia-completes-directed-share-issue-to-nvidia-ce7d5fdcde8df223[marketscreener]

by John F. Heerdink, Jr. March 18, 2026

March 18, 2026 – Oil, Inflation and a Grumpy Fed: Why Wall Street Just Marked Down Its Soft-Landing Fantasy -( $HTFL $LULU $VIX Rise!)

Stocks staged a Fed-day post St. Patty’s Day hungover tantrum Wednesday, as investors discovered that “higher for longer” still means exactly what it sounds like.

Indexes and Rates

The Dow industrials fell sharply, at one point flirting with a 700‑plus point slide, as traders dumped cyclicals and crowded exits in rate‑sensitive corners of the market. The S&P 500 and Nasdaq also retreated, giving back a chunk of this week’s tentative rebound as the post‑PPI wobble turned into a full‑blown re‑pricing of the Fed’s patience. Treasury yields pushed higher along the curve, underscoring that the market heard fewer cuts, not soothing coos, in Wednesday’s message from Constitution Avenue.

The Fed’s Message

The Federal Reserve left its policy rate unchanged in a target range around 3.5% to 3.75%, but it was the fine print that did the damage. Updated projections penciled in only about one rate cut this year as officials nudged inflation forecasts higher, even as they kept unemployment estimates near 4.4%, an awkward mix for anyone still rooting for a painless soft landing. Chair Jerome Powell declined to knight the current mix of firm prices and solid growth as “stagflation,” but he spent plenty of time describing its less lovable cousins, making it clear the bar for easing has crept higher.

Inflation, Oil and Geopolitics

A hotter‑than‑expected producer‑price print on Tuesday had already softened the market’s knees heading into the meeting, and the Fed did little to talk traders off the ledge. Policymakers highlighted the recent oil shock, driven by the conflict with Iran and renewed jitters in the Strait of Hormuz, as a force that could both sap demand and goose headline inflation. Powell noted that as a net energy exporter the U.S. might claw back some of that pain through higher energy profits, a reminder that in 2026, the line between macro risk and oil‑stock bonus is thinner than many strategists care to admit. Crude Oil closed at $98.80/bbl up 3.51% today as the war raged on.

Sector Moves

Energy shares once again played the awkward role of portfolio ballast, with rising crude prices cushioning the blow even as they reinforced the Fed’s inflation worries. Growth and long‑duration tech names, which had been inching higher earlier in the week, lost altitude as higher yields took another bite out of valuation math that had already been stress‑tested by AI enthusiasm. Financials were mixed, with banks enjoying the prospect of fatter net interest margins while their investment‑banking cousins contemplated what a stickier rate backdrop might mean for deal dreams penciled in at lower discount rates.

The Mood on Wall Street

By the closing bell, the mood on trading floors felt less like panic and more like a reluctant syllabus change: same class, tougher grading curve. Volatility indicators stayed elevated, reflecting a market that now expects larger‑than‑normal daily swings as it digests every inflation print and oil headline for clues on whether that lone penciled‑in cut survives the summer. The markets “fear guage’ the CBOE Volatility Index (^VIX) popped to $24.66, +10.24% today. For now, investors are relearning an old lesson: when the Fed says it’s “data dependent” in an environment of hot prices and expensive energy, it usually means the data, not the shareholders, get the benefit of the doubt.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $7.51)

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (March 17) positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). “We are very pleased to see such a meaningful symptom response at 24 weeks in the highest dose of the Phase 1b/2a portion of the RESOLVE study,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “We believe this type of response based on a single administration procedure would represent a compellingly different option for EoE patients. Importantly, the response that we are observing across cohorts 4-9 has increased as patients progress through the study through to week 24. We believe this demonstrates the importance of stable, continuous long-term local steroids in tamping down signs of inflammation quickly and acting on fibrosis in the longer term. Also, as previously reported, we continue to be encouraged by the safety profile that we have observed with EP-104GI. Currently, with 31 patients dosed in the Phase 1b/2a study, and over 220 months of follow up, there have been no reported serious adverse events.”

Modular Medical (MODD $.2168)

Modular Medical recently priced a public offering of 68,098,000 shares of common stock (or pre-funded warrants) alongside warrants to buy an equivalent number of shares, targeting gross proceeds of about 12 million dollars before fees. The combined public offering price of roughly 17.62 cents per share and accompanying warrant comes at a premium to the prevailing market, a rare feat in a sector where financings often resemble clearance sales rather than premium shelf space.
Earlier this month, the company began production of validation lots for its disposable cartridge and infusion set, keeping it on track for a planned commercial launch in the first quarter of 2026, contingent on FDA 510(k) clearance—an event path that positions upcoming regulatory decisions as key stock catalysts.

GeoVax Labs (GOVX, $1.42)

GeoVax announced (Feb. 24) the formation of its Oncology Advisory Board with the appointment of three internationally recognized leaders in immuno-oncology, translational medicine, and clinical development. This Advisory Board will play a central role in guiding the scientific, translational, and clinical advancement of GeoVax’s oncology program, focused primarily on Gedeptin(R), the company’s gene-directed enzyme prodrug therapeutic (GDEPT). GeoVax plans to conduct a Phase 2 trial with Gedeptin in the neoadjuvant setting, pairing it with an immune checkpoint inhibitor (ICI) in locally advanced head and neck squamous cell carcinoma. In parallel, it will be evaluating combination Gedeptin + ICI strategies across additional solid tumor indications.
GeoVax announced on Wednesday, Feb. 18 that it has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin(R) in combination with immune checkpoint inhibitors (ICIs).
On February 17, GOVX issued a statement endorsing the urgent call to action articulated by Rosamund Lewis, MD (WHO Head, Poxviruses Programme) and colleagues in their recently published PLOS Medicine article, “The mpox epidemic is not over: Reducing disproportionate burden in Africa and persistent global risk require a sustained response.” (https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004893&type=printable)
Shares can gap sharply on any trial or regulatory update, positive or negative.

The InterGroup Corporation (INTG, $37.51)

InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO)

Volato Group, Inc. today announced that it has entered into an amendment to its Aircraft Management Services Agreement with flyExclusive, Inc. (“FLYX”) providing for the sale of certain legacy intellectual property assets. The agreement provides for consideration valued at approximately $1.3 million, payable in FLYX Class A common stock, subject to customary conditions. The assets relate to legacy intellectual property developed during earlier stages of the Company’s technology initiatives and are not part of Volato’s current operating platforms. Volato continues to evaluate opportunities to streamline its asset base and focus resources on strategic priorities, including the continued development of its core software platforms and the pending business combination with M2i Global, Inc.
Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $180.40) (NOK, $8.36)

In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
NVIDIA and Nebius Group N.V. (NASDAQ: NBIS) (March 11) announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius.

McDonald’s (MCD, $315.73)

In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Opendoor (OPEN, $5.28)

Opendoor Technologies, a leading e-commerce platform for residential real estate transactions, reported financial results for its fourth quarter and year ended December 31, 2025. They highlighted the following: October 2025 acquisition cohort tracking as best-performing October in Company history; acquisitions increased 46% quarter-over-quarter while inventory days in possession reduced 23%.
Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.

lululemon athletica inc. (LULU, $165.39, +3.84%)

lululemon athletica inc. announced (MARCH 17) the appointment of Chip Bergh, former President and Chief Executive Officer of Levi Strauss & Co., to its Board of Directors, effective immediately. With this addition, lululemon has added five new independent directors to the Board in the last five years, reflecting the Board’s commitment to ongoing refreshment.

Heartflow, Inc. (HTFL, $25.47, +13.10%)

Heartflow, Inc. (HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights included:

Total revenue of $49.1 million, a 40% increase year-over-year
Gross margin of 79.5%, non-GAAP gross margin of 79.9%
Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 million
U.S. installed base of 1,465 accounts as of December 31, 2025
U.S. Plaque installed base of 489 accounts as of December 31, 2025
Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives for Plaque to approximately 75%

The Sources

Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq fall after PPI inflation …”
https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-futures-rise-with-fed-decision-on-deck-225450963.html[finance.yahoo]
(User-provided Yahoo Finance Fed-day recap link – original live blog you referenced)
https://finance.yahoo.com/news/live/stock-market-today-dow-sinks-750-points-sp-500-nasdaq-slide-after-fed-decision-as-powell-touts-inflation-worries-200050703.html[finance.yahoo]
Investopedia – “Stock Market Today: Major Indexes Retreat Ahead of Fed Rate Decision; Inflation Data Lands Hot, Oil Prices Rise; Dow Sheds 450 Points”
https://www.investopedia.com/stock-market-today-dow-jones-s-and-p-500-03182026-11928689[investopedia]
CNBC – “Fed meeting today: Live updates”
https://www.cnbc.com/2026/03/18/fed-meeting-today-live-updates.html[cnbc]
Axios – “Fed keeps rates on hold, signals one rate cut as Iran war stokes …”
https://www.axios.com/2026/03/18/fed-powell-interest-rate[axios]
The New York Times – “Live Updates: Federal Reserve Leaves Interest Rates Unchanged”
https://www.nytimes.com/live/2026/03/18/business/federal-reserve-interest-rates[nytimes]

by John F. Heerdink, Jr. March 18, 2026

Interest Rates on Hold, Nerves Not So Much: How the Fed Is Playing Economic Jenga -( $SPY $VIX $NVDA $SWMR )

The Federal Reserve’s latest rate decision landed not with a bang, but with the kind of carefully measured thud Wall Street has come to admire: steady, data-dependent, and just hawkish enough to keep the bond vigilantes awake.

Fed Holds the Line as Shocks Roll In

Policymakers left the benchmark rate unchanged, effectively extending their 2026 pause and signaling that, in a world of oil shocks and fragile job data, doing nothing can still be a very deliberate choice. With geopolitical tensions in Iran pushing crude higher and inflation still reluctant to sit comfortably at 2%, officials emphasized uncertainty rather than victory laps, underscoring that the path to future cuts is now more winding than markets had hoped.

The Fed’s messaging leaned on “higher for longer if needed,” but it stopped short of threatening fresh hikes, a nuance that equity investors heard as: keep your spreadsheets flexible and your hopes modest. Futures pricing now reflects strong odds that policy will stay on hold near the current 3.5%–3.75% corridor for longer, with rate-cut expectations pushed further into the year and, for some scenarios, into 2027.

Inflation, Oil, and the Art of Looking Through

Behind the steady hand is a central bank trying to distinguish between a durable inflation problem and what it still prefers to view as “transitory, this time we mean it” energy shocks. Economists note that while headline inflation is likely to drift higher on the back of oil, the Fed appears more focused on whether core price pressures and expectations stay anchored, rather than chasing every blip in crude.

That stance reflects a quiet confidence that markets can absorb short-term turbulence without derailing the expansion, even if the job numbers have turned patchier and corporate guidance has grown more cautious. The message to CFOs and portfolio managers alike: volatility is back on the menu, but the Fed is not yet ready to re-open the rate-hike playbook. The market’s ‘fear guage’, The CBOE Volatility Index (^VIX), is up ~+18% over the last month.

NVIDIA: The Market’s Favorite Shock Absorber

If the macro backdrop is murky, NVIDIA (NVDA) continues to play the role of Wall Street’s preferred shock absorber, where every dip is treated less like a warning and more like an unscheduled buying opportunity.
Shares have consolidated just below recent highs in March, with trading volumes remaining heavy as investors weigh dizzying AI growth projections against a market that knows how to price perfection.

At recent levels in the low- to mid-180s, the stock has traded through bouts of profit-taking without losing its broader uptrend, suggesting that conviction buyers still view AI infrastructure as a secular story rather than a cyclical whim. Commentary around the company’s latest GTC showcase has only reinforced that narrative, with investors treating long-term revenue ambitions and expansion into new compute frontiers as the baseline, not the bull case.

Swarmer’s IPO: From Launchpad to Stratosphere

While the Fed is standing still, Swarmer, Inc. (SWMR) is doing the opposite: the drone-software IPO roared onto the Nasdaq with the kind of first-day surge that makes veteran traders quietly recheck their screens. Priced at just 5 dollars a share, Swarmer opened significantly higher and finished its debut session near 31 dollars, delivering a gain of more than 500% and instantly landing on the leaderboard of this cycle’s most eye-catching IPO pops. Today the stocks has charged up further to an intraday high of $64.72.

The company’s pitch is as aggressive as its chart: AI software that allows a single operator to coordinate swarms of drones, a theme that directly taps into rising defense-tech demand amid global conflicts. Revenue remains modest and losses sizable, but that did little to dampen appetite from traders willing to pay battlefield-multiple prices for what they see as a high-conviction play on autonomous systems and modern warfare.

The Sources

Here’s a clean, numbered list of useful sources with links you can reference or drop at the end of your article:

Federal Reserve holds interest rates steady – Yahoo Finance
https://finance.yahoo.com/news/us-federal-holds-interest-rates-200556640.html[finance.yahoo]
Fed meeting: live coverage and outlook around holding rates – Yahoo Finance
https://finance.yahoo.com/news/live/fed-meeting-live-updates-federal-reserve-expected-to-hold-rates-steady-offer-updated-outlook[finance.yahoo]
Fed expected to hold rates steady due to war and energy shock – Yahoo Finance (video)
https://finance.yahoo.com/video/fed-expected-hold-rates-steady-134100647.html[finance.yahoo]
Fed Chair Powell says interest rates on hold amid economic uncertainty – Yahoo Finance
https://finance.yahoo.com/news/powell-federal-stay-hold-amid-173247325.html[finance.yahoo]
Swarmer (SWMR) stock rockets in IPO debut – MEXC News
https://www.mexc.com/news/955248[mexc]
Why SWMR stock soared over 500% in Nasdaq debut – Stocktwits News
https://stocktwits.com/news-articles/markets/equity/swarmer-ipo-stock-surge-drone-war-demand-ceo/cZ3eHwKRIX6[stocktwits]
Swarmer IPO price action and percentage surge – Barron’s
https://www.barrons.com/articles/swarmer-swmr-ipo-stock-price-ticker-7b0d2e1e[barrons]
Drone-software company Swarmer surges in IPO debut – Investing.com
https://www.investing.com/news/stock-market-news/dronesoftware-company-swarmer-surges-250-in-ipo-debut-after-opening-at-1250-456[investing]
NVIDIA at GTC 2026: AI expansion and partnerships – Investing.com
https://www.investing.com/news/transcripts/nvidia-at-gtc-2026-ai-expansion-and-strategic-partnerships-93CH-4564073[investing]
Nvidia doubles AI hardware forecast, touts new inferencing chip – Investor’s Business Daily
https://www.investors.com/news/technology/nvidia-stock-nvda-gtc-2026-keynote/[investors]
Veteran analyst’s blunt message on Nvidia stock after GTC – TheStreet
https://www.thestreet.com/investing/stocks/veteran-analyst-sends-blunt-message-on-nvidia-stock-after-gtc[thestreet]
What to expect from Nvidia’s GTC, the “Woodstock of AI” – Investopedia
https://www.investopedia.com/what-to-expect-from-nvidia-gtc-2026-gpu-technology-conference-nvda-woodstock-of-ai-11926068[investopedia]

by John F. Heerdink, Jr. March 18, 2026

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets.

A New Board for a New Radiopharma Moment

NAYA Therapeutics, a clinical‑stage biopharmaceutical company, is indeed building therapies around astatine‑211 targeted alpha emitters and NK cell‑engaging bifunctional antibodies, aiming squarely at difficult‑to‑treat cancers. In a sector where capital, credibility, and clinical execution can move as quickly as a PET scan, assembling a seasoned board is less a vanity move and more a prerequisite for serious participation in the radiopharma arms race. The company’s newly announced “world‑class” board is designed to match that ambition, blending deep scientific, clinical, and governance experience to navigate an increasingly competitive radiopharmaceutical landscape. The newly elected Naya board members are:

Ely Benaim, MD, an accomplished physician-executive with over 25 years of experience in oncology drug development and clinical leadership. A pediatric hematologist/oncologist, he has held senior roles at leading biotechnology and pharmaceutical companies, including Amgen, Millennium/Takeda, Novocure, and SonALAsense. Dr. Benaim currently serves as Chief Medical Officer of Henlius Fosun USA, where he leads U.S. clinical strategy and development initiatives. His career is distinguished by bringing multiple innovative cancer treatments from early clinical trials to FDA approval, improving outcomes for patients worldwide
Margarita Chavez, JD, a seasoned biopharmaceutical executive with over 25 years of dealmaking experience in the healthcare industry, including in biotech licensing, IPOs, and acquisitions. Margarita currently serves on the boards of Aligos Therapeutics and chairs the Strategy Committee, Newron Pharmaceuticals and chairs the BD Committee, and Xylo Bio as Board Chair. She is also Managing Partner of Ilustrada Group, a biotech advisory. Margarita served as Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics (acquired by Lilly for $3.2Bn), Alector Therapeutics, Jnana Therapeutics (acquired by Otsuka for $1.1Bn), and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott/AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven, Solvay, and the Lupron franchise. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley.
Anne Lauvergeon, PhD, a leading businesswoman, board member, and political advisor. Anne is the founder and President of ALP (Anne Lauvergeon Partners), an advisory and investment company mostly dedicated to innovation. She has served on over a dozen boards, including American Express, Airbus, Vodafone and TotalEnergies. She was twice named by Time Magazine as one of the 100 most influential people in the world. She previously served as chairman and Chief Executive Officer of global nuclear energy leader AREVA. During her tenure, she initiated the application of nuclear energy to medicine under AREVA Med, which later transformed into radiopharmaceutical leader Orano Med. Some of her previous roles include Partner at Lazard, the world’s largest independent investment bank, President of the French Government’s 2030 Innovation Commission, which oversees €54 billions of planned investment, and Senior Advisor & Deputy Chief-of-Staff to the French President.
Rahul Singhvi, PhD, MBA, a global leader in the life sciences industry. Rahul was previously cofounder & CEO of biomanufacturing company National Resilience, Inc., where he helped raise over $2 Billion. Prior to co-founding Resilience in 2020, Rahul was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship Labs. Before joining Flagship, Rahul served as the Chief Operating Officer of the vaccine business unit at Takeda Pharmaceutical Co., where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. and held several positions with Merck & Co in R&D and manufacturing. Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar. Rahul serves on the Board of Directors for Codexis, and Kairos Pharmaceuticals.

Why Astatine‑211 and NK Cells Have Wall Street’s Attention

NAYA’s focus on astatine‑211 (²¹¹At) targeted alpha therapies taps into one of oncology’s most interesting frontiers: delivering highly potent radiation directly to tumor cells while limiting collateral damage to healthy tissues. Targeted alpha therapy sits alongside the now‑crowded lutetium‑177 space, positioning NAYA in what some strategists see as the “next wave” after today’s first‑generation radiotherapies.

Layer in NK cell‑engaging bifunctional antibodies—aimed at mobilizing innate immunity against tumors—and the platform reads like a checklist of what larger oncology players increasingly seek in acquisition targets: precision, combination potential, and differentiated mechanisms of action.

Radiopharma Dealmaking: From Niche to Feeding Frenzy

If radiopharma once sat in the “interesting, but niche” bucket, recent M&A has moved it firmly into the “board‑mandated strategic priority” column. Over roughly eight months, big pharma snapped up at least four of the sector’s hottest names: Novartis (NVS) acquired Mariana Oncology for around 1 billion dollars, Eli Lilly (LLY) bought Point Biopharma for about 1.4 billion dollars, AstraZeneca (AZN) purchased Fusion Pharmaceuticals for roughly 2.4 billion dollars, and Bristol Myers Squibb (BMY) acquired RayzeBio for approximately 4.1 billion dollars.

Those headline transactions sit atop a broader stack of licensing and collaboration deals, including Novartis’ multibillion‑dollar partnership with PeptiDream and Eli Lilly’s pact with Aktis Oncology that carries up to 1.1 billion dollars in potential milestones, underscoring how aggressively large players are underwriting radiopharma optionality.

Investment Wave Meets Market Expansion

The M&A surge is underpinned by market projections that would make even a jaded analyst reach for a fresh spreadsheet. One forecast pegs the radiopharmaceuticals market growing from about 9.1 billion dollars in 2023 to 26.5 billion dollars by 2031, implying a mid‑teens compound annual growth rate, while other estimates point to nearly 20 percent annual expansion, with the market potentially exceeding 40 billion dollars early in the next decade.

Consultants and strategists point to a sharp rise in clinical programs as a leading indicator: more radiopharma trials today mean more data‑driven licensing and acquisition activity tomorrow, particularly as pivotal readouts create natural “deal windows” for late‑stage assets. For investors, that translates into a sector where innovation cycles and transaction cycles are increasingly synchronized—a combination that tends to keep both bankers and biotech generalists very busy.

Where NAYA Fits in the Radiopharma Playbook

Against that backdrop, NAYA’s decision to spotlight a world‑class board looks less like a press‑release flourish and more like a strategic signal to prospective partners, acquirers, and institutional investors. Companies with targeted radiotherapeutics and immune‑engaging platforms have become prime candidates for either bolt‑on acquisitions or sizable licensing deals, particularly as incumbents race to diversify beyond lutetium and actinium into lead 212 which has a few early clinical successes and astatine‑211: the cleanest, safest, and most scalable alpha isotope. In addition, NAYA’s competitive advantage is a clinical pipeline that avoids the crowded prostate and neuro-endocrine tumors and opens new large markets i.e. hepatocellular carcinoma and multiple myeloma. NAYA also leads the pack among astatine 211 players in implementing a scalable decentralized supply chain.

With these advantages and the fact that the radiopharma field is consolidating at the top and expanding at the base, NAYA’s clinical‑stage profile and sharpened governance bench could position it as an attractive participant in the sector’s next phase, whether that means remaining independent with strategic partnerships or eventually joining the growing list of radiopharma buyouts. For now, at least, the company appears to have given itself something every ambitious oncology player wants in this market: optionality, and a board well‑equipped to use it.

The Sources

NAYA Therapeutics – Astatine‑211 Targeted Alpha Therapies
https://www.nayatx.com/astatine-211-targeted-alpha-therapies[nayatx]
NAYA Therapeutics – Our Team / Board information
https://www.nayatx.com/copy-of-our-team-1[nayatx]
NAYA Therapeutics – Our Team (archived/old)
https://www.nayatx.com/our-team-oldd[nayatx]
Access Newswire – NAYA Therapeutics Announces World-Class Board of Directors
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-announces-world-class-board-of-directors-1148490[accessnewswire]
Access Newswire – NAYA Therapeutics Announces European Research and Manufacturing Hub at Paris-Saclay
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-announces-european-research-and-manufacturing-hub-at-paris-saclay-1146718[accessnewswire]
BioWorld – NAYA Therapeutics unveils GPC3-targeted Astatine‑211 radioimmunotherapy
https://www.bioworld.com/articles/721292-naya-therapeutics-unveils-gpc3-targeted-astatine-211-radioimmunotherapy[bioworld]
1stOncology – NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC) Pipeline with First-in-Class GPC3-Targeted Astatine‑211 Radioimmunotherapy
https://www.1stoncology.com/blog/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-first-in-class-gpc3-targeted-astatine-211-radioimmunotherapy[1stoncology]
FirstWord Pharma – NAYA Therapeutics to Present at the Network for Optimized Astatine‑Labeled Radiopharmaceuticals
https://firstwordpharma.com/story/6515536[firstwordpharma]
Access Newswire – NAYA Therapeutics to Present at the Network for Optimized Astatine‑Labeled Radiopharmaceuticals
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-to-present-at-the-network-for-optimized-astatine-labeled-radiopharmaceuticals-noar-1147082[accessnewswire]
PharmaIndustrial India – NAYA Therapeutics Partners with Alpha Nuclide to Advance Astatine‑211 Cancer Therapies
https://www.pharmaindustrial-india.com/news/-naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-cancer-therapies[pharmaindustrial-india]
FirstWord Pharma – NAYA Announces Partnership with Alpha Nuclide to Support Astatine‑211 Radiopharmaceuticals
https://firstwordpharma.com/story/6320192[firstwordpharma]
PharmiWeb – NAYA Therapeutics Partners With IONETIX to Build a US Production Supply Network for Astatine‑211
https://www.pharmiweb.com/press-release/2025-08-21/naya-therapeutics-partners-with-ionetix-to-build-a-us-production-supply-network-for-astatine-211[pharmiweb]
FirstWord Pharma – NAYA Therapeutics Partners With IONETIX to Build a US Production Supply Network
https://firstwordpharma.com/story/5991246[firstwordpharma]
BioSpace – NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-Targeted Antibody
https://www.biospace.com/press-releases/naya-biosciences-announces-initiation-of-phase-1-2a-clinical-trial-for-its-gpc3-targeted-antibody-ny-303[biospace]
OncoDaily – NAYA Biosciences has Expanded the Oncology Pipeline with Novel Antibody Programs
https://oncodaily.com/insight/219228[oncodaily]
Investing.com – NAYA Biosciences expands oncology pipeline with new antibody
https://www.investing.com/news/company-news/naya-biosciences-expands-oncology-pipeline-with-new-antibody-93CH-3797583[investing]
Finance Yahoo – NAYA Therapeutics Enters into Definitive Agreements to Regain Full Rights to Key Oncology Assets
https://finance.yahoo.com/news/naya-therapeutics-enters-definitive-agreements-130000468.html[finance.yahoo]
StreetInsider – NAYA Biosciences (NAYA) nominates new Board members
https://www.streetinsider.com/Board+Changes/NAYA+Biosciences+(NAYA)+nominates+new+Board+members/24369080.html[18]
Invo Fertility – NAYA Biosciences Announces Nomination of New Board Members
https://invofertility.com/naya-biosciences-announces-nomination-of-new-board-members/[invofertility]
LinkedIn – NAYA Therapeutics Announces World-Class Board of Directors (company post)
https://www.linkedin.com/posts/naya-therapeutics_naya-therapeutics-announces-world-class-board-activity-7439683577744715776-lU_w[linkedin]

by John F. Heerdink, Jr. March 18, 2026

Amazon’s $600 Billion Cloud Dream: Can Wall Street Handle This Much AI Optimism? -( $AMZN $SPY )

Amazon is effectively telling Wall Street that its cloud is no longer just a utility—it is the monetization engine of the AI era, with Andy Jassy sketching a path to an eye‑popping (600) billion dollars in annual AWS revenue by 2036. The catch, of course, is that this future comes with a present‑day price tag: roughly (200) billion dollars of AI‑heavy capex that has some investors clutching their discounted cash flow models a little tighter.

AWS: From Cloud Workhorse to AI Mint

In an internal all‑hands, Jassy said he had long envisioned AWS as a (300) billion‑dollar‑a‑year business within a decade, but now argues that AI demand could reasonably double that target to at least (600) billion by 2036. That revision comes on the back of AWS sales that reached about (128.7) billion dollars in 2025, growing roughly 20 percent year over year and still accelerating as enterprises shift both core and AI workloads into the cloud.

The CEO’s logic is disarmingly simple and mildly immodest: as fast as AWS installs AI capacity, customers are filling it—with generative models, custom workloads, and inference services that are increasingly embedded into everyday applications. If the cloud once sold storage and compute by the yard, the AI phase is closer to selling finished capabilities by the outcome—recommendations delivered, content generated, insights extracted.

The $200 Billion Question for Wall Street

To feed that demand, Amazon is aiming roughly (200) billion dollars of capital spending this year at AWS, with the bulk funneled into AI infrastructure: land, power, data centers, custom chips, servers, and networking. Some of that spend will also backstop surprisingly resilient “non‑AI” workloads, which are still growing faster than the company expected—an inconvenient reminder that the old cloud business refuses to age quietly.

This scale has not exactly soothed the Street’s nerves. Shares sold off earlier this year when management laid out the capex trajectory, as investors did the quick math and realized “AI supercycle” is another way of saying “near‑term margin compression.” Jassy has responded with a mix of patience and pointedness, stressing that the spending is tied to visible demand signals rather than speculative moonshots, and insisting that AWS’ history of matching capacity to usage will translate into healthy long‑term returns on invested capital.

AI Everywhere: From Retail Aisles to Factory Floors

Behind the lofty revenue target is a very grounded thesis: AI is becoming a default feature of almost every business workflow, and AWS intends to sit underneath all of it. On the retail side, Amazon is already pushing generative services like Amazon Bedrock to automate product descriptions, optimize SEO, and hyper‑personalize storefronts—moves that can lift revenue for merchants while quietly boosting AWS usage in the background.

Industrial customers are being courted with “production‑ready” AI at events like Hannover Messe, where AWS is showcasing tools to move manufacturers from pilot projects to fully scaled predictive maintenance, quality control, and automation. In each case, the pattern is the same: as AI models become woven into marketing, logistics, customer service, and analytics, the gravitational pull toward Amazon’s cloud—and its home‑grown chips and orchestration services—gets stronger.

Retail Theater: Drones, Groceries, and the Side Quests

The internal meeting that featured Jassy’s (600) billion‑dollar forecast also touched on some of Amazon’s more visible experiments, the kind that remind investors this is still a retailer with a flair for spectacle. The company expects to notch its one‑millionth drone delivery this year, more than a decade after first teasing airborne packages on “60 Minutes,” suggesting that the future sometimes arrives fashionably late and with a propeller.

Grocery remains a work in progress: Amazon Fresh and Go physical formats that were shuttered earlier this year represented less than one percent of the company’s grocery sales, underscoring how small the experimental brick‑and‑mortar footprint is relative to the broader food ambitions. For now, those efforts function as strategic side quests in a larger game dominated by cloud, advertising, logistics, and the increasingly central AI infrastructure narrative.

The New Narrative: Paying Up for an AI Utility

Underneath the humor of a (600) billion‑dollar “thought experiment” lies a serious repositioning of Amazon’s story for the next decade: from e‑commerce giant with a cloud appendage to AI utility with a global retail laboratory attached. Net sales across the company rose about 12 percent in 2025 to roughly (716.9) billion dollars, but the strategic oxygen on earnings calls and internal briefings is now consumed by AWS’ AI trajectory and the capital required to support it.

For investors, the choice is psychologically simple and financially complex: tolerate years of elevated capex and a bumpier margin profile in exchange for a credible shot at the world’s most profitable AI infrastructure franchise. In other words, Amazon is asking the market to behave like one of its Prime subscribers—pay more upfront, trust the long‑term value, and accept that the really interesting benefits are still loading in the background.

The Sources

[1] Exclusive-Amazon CEO sees AI doubling prior AWS sales … https://finance.yahoo.com/news/exclusive-amazon-ceo-sees-ai-184824914.html
[2] Amazon CEO Andy Jassy sees AI driving AWS revenue to $600 … https://www.storyboard18.com/digital/amazon-ceo-andy-jassy-sees-ai-driving-aws-revenue-to-600-billion-by-2036-report-ws-l-92483.htm
[3] Exclusive-Amazon CEO sees AI doubling his prior AWS sales … https://finance.yahoo.com/news/exclusive-amazon-ceo-sees-ai-184824036.html
[4] Amazon CEO Andy Jassy plans to ‘invest aggressively’ in AI https://finance.yahoo.com/video/amazon-ceo-andy-jassy-plans-224630166.html
[5] Amazon Defends Massive AI Spending, Says New AWS Capacity … https://finance.yahoo.com/news/amazon-defends-massive-ai-spending-143139992.html
[6] Amazon CEO reportedly sees AWS reaching $600B in annual sales … https://finance.yahoo.com/news/amazon-ceo-reportedly-sees-aws-193056637.html
[7] How generative AI and data are redefining retail experiences https://aws.amazon.com/blogs/industries/how-generative-ai-and-data-are-redefining-retail-experiences/
[8] What $200 Billion Means for AWS Through 2026 – Yahoo Finance https://finance.yahoo.com/news/amazon-bets-200-billion-ai-114248383.html
[9] Amazon stock sinks after company touts $200 billion AI spending … https://finance.yahoo.com/news/amazon-stock-sinks-after-company-touts-200-billion-ai-spending-plans-offers-cautious-profit-outlook-173054116.html
[10] Where Amazon stands in the AI race – Yahoo Finance https://finance.yahoo.com/video/where-amazon-stands-ai-race-113055848.html
[11] Amazon Stock Investors Just Got Fantastic News From CEO Andy … https://finance.yahoo.com/news/amazon-stock-investors-just-got-213600360.html
[12] From Pilot to Production: Scaling Industrial AI with AWS at Hannover … https://aws.amazon.com/blogs/industries/aws-at-hannover-messe-2026/
[13] Decoding the Logistics and Cloud Dominance of 2026 https://markets.financialcontent.com/stocks/article/finterra-2026-2-26-amazons-dual-engine-decoding-the-logistics-and-cloud-dominance-of-2026
[14] Amazon Workers Say AI Is Making Their Jobs Harder … – YouTube https://www.youtube.com/watch?v=sfou45zUgE4
[15] Amazon CEO Andy Jassy said that AI will reduce the … – Instagram https://www.instagram.com/p/DVVchTtj2o9/

by John F. Heerdink, Jr. March 17, 2026

March 17, 2026 – Gold Glitters, Yields Flinch: A St. Paddy’s Market Recap With a Wink -( $EPRX $GLD $INTG $LMND $OPEN $SOAR Rise!)

Wall Street spent St. Patrick’s Day edging back into the green, as investors raised a cautious toast to the Federal Reserve and NVIDIA’s AI ambitions rather than to rapid-fire rate cuts.

Indices and macro mood

US stocks advanced for a second straight session, with the Dow, S&P 500, and Nasdaq all higher as Fed week kicked off and investors tried, once again, to buy the dip without calling it that. The move comes after three consecutive weekly declines, suggesting bargain hunters finally decided the pot of gold at the end of this pullback was worth at least a small allocation.

Oil prices popped back above 100 dollars a barrel on renewed Middle East tensions, a reminder that inflation may still have more lives than a Wall Street earnings “adjustment.” Futures and rates markets still largely expect the Fed to hold policy steady at the March meeting, with the real drama reserved for the dot plot and Powell’s tone rather than any change in the target rate.seekingalpha+3

Fed on deck

The Fed’s two-day meeting began today, and the consensus script calls for no move on rates after a trio of cuts to close out last year, even as growth and inflation data keep policymakers uncomfortably alert. Traders are parsing every hint about the timing and pace of any future cuts, well aware that officials have been pushing back on the notion of a swift easing cycle worthy of a St. Paddy’s pub crawl.

In the meantime, steady policy plus firm equity prices has kept “risk-on” alive, if not exactly roaring, with investors favoring large-cap tech and other quality growth names while keeping one eye on the bond market’s leprechaun—real yields.

NVIDIA, GTC, and the AI rainbow

In tech, NVIDIA remained the market’s de facto spiritual leader as its GTC 2026 conference rolled on, drawing another wave of superlatives from Wall Street analysts who long ago stopped pretending to be surprised. CEO Jensen Huang used the San Jose stage to sketch an AI future in which NVIDIA doesn’t just sell picks and shovels for the gold rush, but quietly owns most of the mine, the railroad, and possibly the town council.

Huang and his team outlined demand for Blackwell and related AI platforms that could drive roughly 1 trillion dollars in AI chip and systems sales through 2027, effectively doubling prior long-term order targets and reinforcing the argument that AI capex is not peaking so much as catching a second wind. The stock’s reaction was positive but restrained—more a nod of approval than a euphoric jig—as valuation worries and competition linger, even while major firms reiterate overweight ratings and describe NVIDIA as still “alone at the top of the AI mountain.”

Sector color and corporate undercurrents

Mega-cap tech helped lead the broader market higher, with AI-linked names again providing tailwinds to the Nasdaq as investors leaned back into the “big, profitable, and data-center heavy” trade. Elsewhere, higher crude prices gave energy a modest lift, even as they complicated the inflation narrative that equity bulls would prefer to keep on mute.

Some consumer and communication names saw renewed interest as dip buyers tiptoed in after recent weakness, though the tone remained selective rather than speculative manic—more risk rotation than risk binge. With St. Patrick’s Day falling on the first day of a Fed meeting and in the middle of an AI supercycle conference, the market’s message was relatively clear: enjoy the green, but don’t assume it’s all luck.

Gold shone a little brighter than shamrock foil today, while silver lost some of its recent luster, and the 10‑year quietly eased as Fed week got underway.150currency+3

Gold Shines, Silver declines

Gold hovered just above the 5,000‑dollar line, with spot prices around 5,030 dollars an ounce, essentially holding the psychological level even as geopolitical risk and rate expectations continued their tug‑of‑war. Silver, by contrast, traded closer to the low‑80s per ounce, slipping on the day and reminding investors that not every metal gets to be the safe‑haven hero in the same session.

10‑year Treasury

In bonds, the 10‑year Treasury yield edged down to roughly the low‑4.2 percent area, marking a modest pullback from last week’s highs as traders positioned ahead of the Fed’s rate decision and digested still‑elevated inflation prints. The move kept real yields from breaking higher and offered just enough relief to growth and AI‑heavy names to keep the “higher for longer” narrative from completely drowning out the St. Patrick’s Day cheer..

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $7.58, +2.57%)

Modular Medical (MODD $.2305)

Modular Medical recently priced a public offering of 68,098,000 shares of common stock (or pre-funded warrants) alongside warrants to buy an equivalent number of shares, targeting gross proceeds of about 12 million dollars before fees. The combined public offering price of roughly 17.62 cents per share and accompanying warrant comes at a premium to the prevailing market, a rare feat in a sector where financings often resemble clearance sales rather than premium shelf space.
Earlier this month, the company began production of validation lots for its disposable cartridge and infusion set, keeping it on track for a planned commercial launch in the first quarter of 2026, contingent on FDA 510(k) clearance—an event path that positions upcoming regulatory decisions as key stock catalysts.

GeoVax Labs (GOVX, $1.68)

GeoVax announced (Feb. 24) the formation of its Oncology Advisory Board with the appointment of three internationally recognized leaders in immuno-oncology, translational medicine, and clinical development. This Advisory Board will play a central role in guiding the scientific, translational, and clinical advancement of GeoVax’s oncology program, focused primarily on Gedeptin(R), the company’s gene-directed enzyme prodrug therapeutic (GDEPT). GeoVax plans to conduct a Phase 2 trial with Gedeptin in the neoadjuvant setting, pairing it with an immune checkpoint inhibitor (ICI) in locally advanced head and neck squamous cell carcinoma. In parallel, it will be evaluating combination Gedeptin + ICI strategies across additional solid tumor indications.
GeoVax announced on Wednesday, Feb. 18 that it has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin(R) in combination with immune checkpoint inhibitors (ICIs).
On February 17, GOVX issued a statement endorsing the urgent call to action articulated by Rosamund Lewis, MD (WHO Head, Poxviruses Programme) and colleagues in their recently published PLOS Medicine article, “The mpox epidemic is not over: Reducing disproportionate burden in Africa and persistent global risk require a sustained response.” (https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004893&type=printable)
Shares can gap sharply on any trial or regulatory update, positive or negative.

The InterGroup Corporation (INTG, $38.88, +1.70%)

InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Volato Group, Inc. (SOAR, +.22%) & M2i Global, Inc. (MTWO)

Volato Group, Inc. today announced that it has entered into an amendment to its Aircraft Management Services Agreement with flyExclusive, Inc. (“FLYX”) providing for the sale of certain legacy intellectual property assets. The agreement provides for consideration valued at approximately $1.3 million, payable in FLYX Class A common stock, subject to customary conditions. The assets relate to legacy intellectual property developed during earlier stages of the Company’s technology initiatives and are not part of Volato’s current operating platforms. Volato continues to evaluate opportunities to streamline its asset base and focus resources on strategic priorities, including the continued development of its core software platforms and the pending business combination with M2i Global, Inc.
Volato and M2i Global reaffirmed their goal of closing their business combination in the first quarter of 2026, citing steady advancement through SEC review and integration planning as they move toward a combined listing. The deal, originally announced in 2025, will effectively transition Volato from a pure‑play private aviation operator into a diversified platform spanning aviation technology and critical minerals, with M2i shareholders expected to own the majority of the combined entity. Operationally, the partnership is already visible: the two companies recently initiated their first shipment of titanium ore from Western Australia to the United States from Titanium X, underscoring how the critical‑minerals vertical could become a meaningful growth engine as domestic supply‑chain security rises in strategic importance.
On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $181.93) (NOK, $8.55)

In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
NVIDIA and Nebius Group N.V. (NASDAQ: NBIS) (March 11) announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius.

McDonald’s (MCD, $326.30)

In the run-up to World Protein Day on 27th February, McDonald’s India (West & South), owned and operated by Westlife Foodworld, is celebrating Protein Week, reinforcing its leadership in nutrition-led innovation. Making protein more accessible, affordable and customizable, Indian consumers can use the McDonald’s app to explore these nutritious offerings and avail of protein burgers starting at just INR 69. Enhancing this convenience, consumers ordering via McDelivery can also enjoy free delivery on the Protein Plus meal range.

Opendoor (OPEN, $5.56, +7.34%)

Opendoor Technologies, a leading e-commerce platform for residential real estate transactions, reported financial results for its fourth quarter and year ended December 31, 2025. They highlighted the following: October 2025 acquisition cohort tracking as best-performing October in Company history; acquisitions increased 46% quarter-over-quarter while inventory days in possession reduced 23%.
Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.

Lemonade (LMND, $66.87, +15.81%)

Lemonade delivers AI-powered renters, pet, car, homeowners, and life insurance across the US and EU. We process claims instantly, keep costs low, and donate unused premiums to causes selected by our community, as part of the annual Giveback program.

The Sources

Here’s a clean, numbered list of key sources with links you can reference for today’s piece:

Reuters – “Trump demands other countries help secure vital Strait of Hormuz as Iran vows defiance”
https://www.reuters.com/world/middle-east/trump-calls-allies-help-secure-strait-hormuz-iran-vows-step-up-retaliation-2026-03-15/[reuters]
Yahoo Finance – “Stock market today: Dow, S&P 500, Nasdaq futures falter, oil slides as Wall Street weighs Iran war signals”
https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-nasdaq-futures-falter-oil-slides-as-wall-street-weighs-iran-war-signals-202450040.html[finance.yahoo]
Yahoo Finance – “Dow, S&P 500 end lower, oil slides as Wall Street weighs Iran war signals”
https://finance.yahoo.com/news/live/stock-market-today-dow-sp-500-end-lower-oil-slides-as-wall-street-weighs-iran-war-signals-200450413.html[finance.yahoo]
Yahoo Finance – “Oil Slides as Global Leaders Seen Acting to Blunt Supply Shock”
https://finance.yahoo.com/news/oil-slides-trump-seeks-ease-233049150.html[finance.yahoo]
Yahoo Finance (video) – “Oil Falls After Trump Says War Will End ‘Very Soon’”
https://finance.yahoo.com/video/oil-falls-trump-says-war-072055488.html[finance.yahoo]
U.S. News – “US Officials Predict Quick End to Iran War, While Tehran Says It Can Fight On”
https://www.usnews.com/news/world/articles/2026-03-15/trump-warns-of-more-strikes-on-irans-kharg-island-pressures-allies-to-secure-oil-routes[usnews]
AP News – “Trump says he’s asked ‘about 7’ countries to join coalition to police Iran’s Strait of Hormuz”
https://apnews.com/article/iran-iraq-us-trump-march-15-2026-9bbed3c906146844be08fdfd02595754[apnews]
The New York Times – “Iran War Live Updates: Israel Expands Lebanon Offensive; Trump’s Oil, NATO Warnings”
https://www.nytimes.com/live/2026/03/16/world/iran-war-trump-oil-lebanon[nytimes]
CNBC – “Treasury yields move higher amid rising oil and labor costs”
https://www.cnbc.com/2026/03/05/us-treasury-yields-investors-fears-around-us-iran-war.html[cnbc]
CNBC – “10-year Treasury yield falls as oil reverses spike”
https://www.cnbc.com/2026/03/09/us-treasury-yields-investors-monitor-iran-war-and-soaring-oil-price.html[cnbc]
CNBC – “Treasury yields: investors weigh escalating U.S.-Iran war”
https://www.cnbc.com/2026/03/03/treasury-yields-investors-weigh-escalating-us-iran-war.html[cnbc]
Yahoo Finance – “Trump admin weighs options to lower oil prices amid Iran conflict” (video)
https://finance.yahoo.com/video/trump-admin-weighs-options-lower-194302837.html[finance.yahoo]
Firstonline – “Stock Market Today, March 16: Europe recovers, following Wall Street; oil slows”
https://www.firstonline.info/en/stock-market-today-March-16-Europe-recovers-in-the-wake-of-Wall-Street-oil-slows/[firstonline]

by John F. Heerdink, Jr. March 17, 2026

Eupraxia’s Six-Month Data Put EP-104GI On The Map – And EPRX On More Screens -( $EPRX $IBB $SNY $XBI )

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is behaving less like a sleepy small-cap from Victoria and more like a company auditioning for prime time in the EoE treatment lineup. With six‑month symptom data from its RESOLVE trial now in hand and a fortified balance sheet coming out of 2025, the pieces are lining up for a pivotal second half of 2026.

Six Months In: Symptoms Don’t Just Improve, They Keep Improving

The latest RESOLVE Part A update focuses on the two highest-dose cohorts of EP‑104GI, Eupraxia’s extended‑release fluticasone injected directly into the esophageal wall. In the highest-dose Cohort 9 (20 x 8 mg), patients achieved an average 4‑point reduction on the Straumann Dysphagia Index (SDI) at 24 weeks; clinical remission is defined as a 3‑point reduction, so the bar wasn’t just cleared, it was given some air.

Pooling cohorts with at least 12 injections (cohorts 4–9), Eupraxia reports clinical remission rates of 59% at 12 weeks, 76% at 24 weeks, and 67% at 52 weeks after a single treatment – an unusual durability profile in a disease accustomed to weekly therapies. i.e Sanofi’s Dupixent that they reported they enjoyed approximately 17.7 billion dollars in sales over the last 12 months. The fact that symptom benefit appears strongest at 24 weeks underscores what management has hinted at all along: EP‑104GI is designed as a “long game” asset where efficacy builds, not fades, over time.

Cleaning Up The Delivery, Clarifying The Signal

Not all high‑dose cohorts are created equal, and Eupraxia’s delivery hardware has now had its own “version upgrade.” Earlier data from a 6 mg per‑site cohort were clouded by catheter clogging, prompting the company to re‑run that dose level with a larger 19‑gauge catheter that is now standard going forward. In this “8b” refresh, patients saw an average SDI reduction of roughly 3.8 points at 12 weeks, compared with a negligible change in the original 6 mg cohort, neatly tying the earlier aberration to under‑delivery rather than under‑performance.

Taken together, the 6 mg and 8 mg cohorts now show a consistent dose‑response in both symptom relief and histologic improvement, with several patients maintaining clinical remission out to one year after a single administration. For investors, the message is straightforward: the doses now being used in the randomized Part B study are the same ones generating the cleanest and most compelling data.

Safety Profile: Long Follow-Up, Short Adverse Event List

For any steroid‑based approach, safety is where the skepticism usually gathers – yet that’s precisely where EP‑104GI has been the least dramatic. Across 31 treated patients and more than 220 patient‑months of follow‑up, Eupraxia reports no serious adverse events and, notably, none of the usual steroid‑related suspects such as candidiasis, adrenal insufficiency or glucose dysregulation, even in a diabetic patient.

The highest dose tested, 8 mg per site, has been described as well tolerated, with no new safety signals emerging as patients move out to the six‑ and twelve‑month marks. In an era where black‑box warnings can wipe out years of R&D value in a single line of fine print, the absence of late‑breaking safety surprises is quietly becoming one of EP‑104GI’s more valuable attributes.

From Pivotal 2025 To Pivotal 2026: The Financial Runway

The six‑month data would matter less if Eupraxia were racing the clock on its cash balance; instead, 2025’s “pivotal year” has given the company room to maneuver. The firm ended 2025 with roughly 80.5 million in cash, up sharply from 33.1 million a year earlier, thanks in part to recent financings explicitly aimed at driving EP‑104GI through key mid‑stage milestones.

Management now guides that existing cash plus expected warrant exercises should fund operations into the second half of 2028, comfortably beyond the Phase 2b readout in the second half of 2026 and into the next wave of clinical programs. For a clinical‑stage company, that kind of runway allows the science – not the ATM – to dictate the news flow.

Eye On The Next Catalyst: Phase 2b In 2H26

All of this work in Part A is effectively a dress rehearsal for the main event: the placebo‑controlled Phase 2b portion of RESOLVE. The ongoing Part B is enrolling 120 patients randomized to placebo, a 20 x 6 mg arm, and a 20 x 8 mg arm, with a six‑month unblinding planned and top‑line data expected in the second half of 2026.

With Part A already showing remission rates in the mid‑double digits and six‑month SDI reductions that exceed the clinical remission threshold, the bar for Phase 2b is now less about “does it work?” and more about “how competitive can it be versus weekly biologics in a commercial setting?” If EP‑104GI can deliver once‑yearly or near‑annual dosing with a profile that stacks up respectably against current leaders, EoE could evolve from a niche opportunity to the first leg of a broader franchise.

Beyond EoE: A Platform Quietly Building

EP‑104GI may be grabbing the headlines, but Eupraxia’s Diffusphere technology is the engine behind the story. The same microsphere‑based platform has already carried EP‑104IAR through a Phase 2b trial in knee osteoarthritis, where the program met its primary endpoint and three of four secondary endpoints, suggesting that “long‑acting local steroid delivery” is not a one‑off idea.

Management has pointed to additional gastrointestinal and inflammatory joint indications, as well as oncology‑focused candidates, as logical extensions; analysts, for now, have tended to model only a subset of that potential, leaving pipeline expansion as unmodeled upside. In other words, it is believed that EP‑104GI is not just a product candidate – it is a proof‑of‑concept for a platform that may ultimately outgrow its first indication.

Analyst Playbook: Three Bulls, Three Targets

On the Street, three firms are now effectively rowing in the same direction on Eupraxia (NASDAQ: EPRX), each with a bullish stance and double‑digit upside targets. Craig‑Hallum’s Albert Lowe reiterates a Buy rating with a 12‑month price target of 14 dollars, highlighting high rates of clinical remission at go‑forward Phase IIb doses and framing EP‑104GI as a potential “best in disease” therapy in eosinophilic esophagitis. Raymond James, led by Martin Auster, MD, keeps a Strong Buy (SB1) rating and an 18 dollar target, arguing that the latest high‑dose RESOLVE Part A data are “supportive and incremental,” reinforce a clean safety profile, and leave the program well‑positioned heading into placebo‑controlled Part B data in 2H26.

Cantor Fitzgerald’s Kristen Kluska rounds out the trio with an Overweight rating and the most aggressive target at 19 dollars, based on a probability‑adjusted DCF that assumes EP‑104GI can support a multi‑billion‑dollar opportunity if upcoming Phase 2b data cooperate. Her team calls EPRX a “must own” ahead of the 3Q26 readout and notes that every 10‑percentage‑point increase in probability of success adds roughly six dollars to their DCF‑derived valuation, underscoring just how much leverage sits in the data. Put together, the three firms are less debating direction than velocity: all see material upside from here; the only real disagreement is how quickly the market decides to price it in. *** Contact these three firms to gain access to the complete reports. ***

The Market’s “Must-Watch” List Just Got Longer

For many well-informed biotech investors, Eupraxia’s (NASDAQ: EPRX) latest update checks off several key boxes: a clear dose‑response, durable remission out to one year, an increasingly well‑defined safety profile, and enough capital to see the program through a critical data readout. The sample sizes in Part A remain small, and Phase 2b will need to confirm these encouraging trends in a larger, placebo‑controlled setting, but the risk‑reward profile is shifting from “speculative idea” toward “under‑followed late‑stage asset.”

In a market where many EoE therapies ask patients for unwavering weekly loyalty, EP‑104GI is offering something different: a shot at durable control with a treatment cadence closer to a calendar reminder than a lifestyle. For a growing segment of healthcare investors, that may be reason enough to keep Eupraxia on the screen between now and the Phase 2b unveiling in the second half of 2026.

The Sources

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in the EP-104GI RESOLVE Trial – Finance Yahoo
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-six-month-110000698.html
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results – Finance Yahoo
https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-fourth-quarter-010300777.html
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in the EP-104GI RESOLVE Trial – GlobeNewswire
https://www.globenewswire.com/news-release/2026/03/13/3255235/0/en/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-highest-dose-cohort-in-the-ep-104gi-resolve-trial.html
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results – GlobeNewswire
https://www.globenewswire.com/news-release/2026/03/13/3255235/0/en/eupraxia-pharmaceuticals-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update.html
Stock Titan summary of Eupraxia 24-week EoE trial data
https://www.stocktitan.net/news/EPRX/eupraxia-pharmaceuticals-reports-six-month-symptom-data-from-the-bs820zazcdnz.html
TipRanks news: Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI
https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-posts-strong-six-month-eoe-data-for-ep-104gi-as-resolve-trial-advances
ClinicalTrials.gov – EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE, NCT05608681)
https://clinicaltrials.gov/study/NCT05608681
Eupraxia Pharmaceuticals corporate website
https://eupraxiapharma.com
Cantor Fitzgerald March 17, 2026 Research Update on Eupraxia (EP-104GI Six-Month High Dose Data)
Raymond James March 17, 2026 Research Update on Eupraxia (Supportive Incremental Data Update from RESOLVE Part A)
Craig-Hallum March 17, 2026 Company Note on Eupraxia (High Rates of Clinical Remission at Go-Forward Doses)

All Posts

A Rebound In A Slump

The iPhone 17 Effect

From Discounts To Discipline

Market Share Moves And Rivals

What It Means For Investors

The Sources

India’s New Love Language: Collateral

A Trillion-Dollar Piggy Bank Unlocks

Policy Tailwinds and Competitive Fire

From Stigma to Strategy

What It Signals for Investors

The Sources

Parkinson’s Bet Draws Fresh Capital

Fueling a Registrational Parkinson’s Trial

The Polymer Platform Behind the Pitch

Warrant Sweetener Extends the Runway

SER Shares Perk Up After Hours

A Small-Cap Biotech with Big-Cap Ambitions

The Sources

BEAD Money Meets BABA Reality

KGPCo Steps Into the Fast Lane

Nokia’s Compliance Edge Becomes a Commercial Weapon

NVDA’s $1 Billion Signal: AI Meets Fiber

Speed, Compliance, and the First-Mover Advantage

The Quiet Power of the Integrator

The Sources

Indexes and Rates

The Fed’s Message

Inflation, Oil and Geopolitics

Sector Moves

The Mood on Wall Street

VP Watchlist Updates

Eupraxia Pharmaceuticals (EPRX, $7.51)

Modular Medical (MODD $.2168)

GeoVax Labs (GOVX, $1.42)

The InterGroup Corporation (INTG, $37.51)

Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO)

NVIDIA (NVDA, $180.40) (NOK, $8.36)

McDonald’s (MCD, $315.73)

Opendoor (OPEN, $5.28)

lululemon athletica inc. (LULU, $165.39, +3.84%)

Heartflow, Inc. (HTFL, $25.47, +13.10%)

The Sources

Fed Holds the Line as Shocks Roll In

Inflation, Oil, and the Art of Looking Through

NVIDIA: The Market’s Favorite Shock Absorber

Swarmer’s IPO: From Launchpad to Stratosphere

The Sources

A New Board for a New Radiopharma Moment

Why Astatine‑211 and NK Cells Have Wall Street’s Attention

Radiopharma Dealmaking: From Niche to Feeding Frenzy

Investment Wave Meets Market Expansion

Where NAYA Fits in the Radiopharma Playbook

The Sources

AWS: From Cloud Workhorse to AI Mint

The $200 Billion Question for Wall Street

AI Everywhere: From Retail Aisles to Factory Floors

Retail Theater: Drones, Groceries, and the Side Quests

The New Narrative: Paying Up for an AI Utility

The Sources

Indices and macro mood

Fed on deck

NVIDIA, GTC, and the AI rainbow

Sector color and corporate undercurrents

Gold Shines, Silver declines

10‑year Treasury

VP Watchlist Updates

Eupraxia Pharmaceuticals (EPRX, $7.58, +2.57%)

Modular Medical (MODD $.2305)

GeoVax Labs (GOVX, $1.68)

The InterGroup Corporation (INTG, $38.88, +1.70%)

Volato Group, Inc. (SOAR, +.22%) & M2i Global, Inc. (MTWO)

NVIDIA (NVDA, $181.93) (NOK, $8.55)

McDonald’s (MCD, $326.30)

Opendoor (OPEN, $5.56, +7.34%)

Lemonade (LMND, $66.87, +15.81%)

The Sources

Six Months In: Symptoms Don’t Just Improve, They Keep Improving

Cleaning Up The Delivery, Clarifying The Signal